Anti-PM/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma

Clinica Chimica Acta

Volumn 411, Issue 13-14, 2010, Pages 965-971

  Maes, L ^a   Blockmans, D ^a   Verschueren, P ^a   Westhovens, R ^a   Op De Beeck K ^a   Vermeersch, P ^a   Van den Bergh, K ^a   Burlingame, R W ^b   Mahler, M ^c   Bossuyt, X ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b INOVA DIAGNOSTICS INC   (United States)

^c DR FOOKE Laboratories Gmbh ^*  (Germany)

Author keywords

Autoantibodies; PM scl; RNA Polymerase III; Systemic sclerosis

Indexed keywords

CENTROMERE ANTIBODY; DNA DIRECTED RNA POLYMERASE III; SCL 70 ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CLINICAL EVALUATION; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SYSTEMIC SCLEROSIS;

AGED; AGED, 80 AND OVER; ANTIBODIES; AUTOIMMUNE DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXORIBONUCLEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC;

EID: 77952552878     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.03.018     Document Type: Article

References (24)

1. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003.
2. Ho K.T., Reveille J.D. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003, 5:80-93.
3. Koenig M., Dieudé M., Senécal J.L. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008, 7:588-593.
4. Mahler M., Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007, 6:432-437.
5. Bluthner M., Mahler M., Muller D.B., Dunzl H., Bautz F.A. Identification of an alpha-helical epitope region on the heterochromatin p25beta autoantigen using immobilized overlapping synthetic peptides. J Mol Med 2000, 78:47-54.
6. Mahler M., Fritzler M.J. PM1-alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?. Autoimmun Rev 2009, 8:373-378.
7. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23:581-590.
8. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
9. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002, 46:328-346.
10. Bohan A., Peter J.B., Bowman R.L., Pearson C.M. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977, 56:255-286.
11. Alarcón-Segovia D., Cardiel M.H. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989, 16:328-334.
12. Vitali C., Bombardieri S., Jonsson R., et al. European Study Group on Classification Criteria for Sjogren's Syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
13. Mewis A., Marien G., Blanckaert N., Bossuyt X. Evaluation of a dot-blot method for identification of antibodies against extractable nuclear antigens and anti-cytoplasmic antibodies. Clin Chem 1999, 45:311-312.
14. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 1970, 227:680-685.
15. Van den Bergh K., Hooikaas H., Blockmans D., et al. Heterogeneous nuclear ribonucleoprotein H1, a novel nuclear autoantigen. Clin Chem 2009, 55:946-954.
16. Genth E., Mierau R., Genetzky P., et al. Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum 1990, 33:657-665.
17. Oddis C.V., Okano Y., Rudert W.A., Trucco M., Duquesnoy R.J., Medsger T.A. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum 1992, 35:1211-1217.
18. Selva-O'callaghan A., Labrador-Horrillo M., Solans-Laque R., Simeon-Aznar C.P., Martinez-Gomez X., Vilardell-Tarres M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 2006, 55:791-798.
19. Meyer O., De Chaisemartin L., Nicaise-Roland P., et al. Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol 2010, 37:125-130.
20. Hanke K., Bruckner C.S., Dahnrich C., et al. Antibodies against PM/Scl-5 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther 2009, 11:R22.
21. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42.
22. Cavazanna I., Angela C., Paolo A., Stefania Z., Angela T., Franco F. Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev 2009, 8:580-584.
23. Bunn C.C., Denton C.P., Shi-Wen X., Knight C., Black C.M. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998, 37:15-20.
24. Yamasaki Y., Honkanen-Scott M., Hernandez L., et al. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 2006, 54:3051-3056.